通过祖先序列重建鉴定的增强型凝血因子IX变异体的人源化与功能表征
研究通过域交换和残基替换筛选,发现An96中5个氨基酸替换足以保留其增强活性,再叠加Padua突变后获得ET9,其比活性较hFIX高51倍;AAV2/8-ET9治疗血友病B小鼠的血浆FIX活性与AAV2/8-An96-Padua相当,且较AAV2/8-hFIX-Padua高10倍。
要点
- An96的42个氨基酸替换中,5个足以在人FIX背景中保留其增强活性。
- 叠加Padua突变后比活性再增5倍,候选分子ET9比活性较hFIX高51倍。
- AAV2/8-ET9在血友病B小鼠中产生的血浆FIX活性与AAV2/8-An96-Padua相当,较AAV2/8-hFIX-Padua高10倍。
核心结论
- 从计算推断的古代FIX序列出发,鉴定出赋予活性增强的新氨基酸替换,并转化为高 potency 的AAV-FIX基因治疗盒。
- 该祖先序列重建发现与序列映射优化方法代表了一个有前景的平台,可用于更广泛的蛋白质药物和基因治疗候选优化。
研究设计与样本
- 采用还原论筛选方法,包括域交换和扫描残基替换,并以一期法FIX活性测定为指导。
- 对顶级候选进行体外表征,包括重组高纯度制备、比活性测定和酶动力学分析。
- 最终候选被包装入腺相关病毒(AAV)载体并递送至血友病B小鼠。
主要发现
- An96中42个氨基酸替换中的5个似乎足以在人FIX变异体中保留An96的增强活性。
- 额外替换Padua变异使比活性进一步增加5倍。
- 候选分子ET9的比活性较hFIX高51倍。
- AAV2/8-ET9治疗的血友病B小鼠产生的血浆FIX活性与先前观察到的AAV2/8-An96-Padua相当,后者较AAV2/8-hFIX-Padua高10倍。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Laboratory resurrection of ancient coagulation factor (F) IX variants generated through ancestral sequence reconstruction led to the discovery of a FIX variant, designated An96, which possesses enhanced specific activity independent of and additive to that provided by human p.Arg384Lys, referred to as FIX-Padua. OBJECTIVES: The goal of the current study was to identify the amino acid substitution(s) responsible for the enhanced activity of An96 and create a humanized An96 FIX transgene for gene therapy application. METHODS: Reductionist screening approaches, including domain swapping and scanning residue substitution, were used and guided by one-stage FIX activity assays. In vitro characterization of top candidates included recombinant high-purity preparation, specific activity determination, and enzyme kinetic analysis. Final candidates were packaged into adeno-associated viral (AAV) vectors and delivered to hemophilia B mice. RESULTS: Five of 42 total amino acid substitutions in An96 appear sufficient to retain the enhanced activity of An96 in an otherwise human FIX variant. Additional substitution of the Padua variant further increased the specific activity 5-fold. This candidate, designated ET9, demonstrated 51-fold greater specific activity than hFIX. AAV2/8-ET9 treated hemophilia B mice produced plasma FIX activities equivalent to those observed previously for AAV2/8-An96-Padua, which were 10-fold higher than AAV2/8-hFIX-Padua. CONCLUSION: Starting from computationally inferred ancient FIX sequences, novel amino acid substitutions conferring activity enhancement were identified and translated into an AAV-FIX gene therapy cassette demonstrating high potency. This ancestral sequence reconstruction discovery and sequence mapping refinement approach represents a promising platform for broader protein drug and gene therapy candidate optimization.
引用
- Coyle CW, Knight KA, Brown HC, et al. Humanization and functional characterization of enhanced coagulation factor IX variants identified through ancestral sequence reconstruction. J Thromb Haemost. 2023. PMID: 38016519. doi:10.1016/j.jtha.2023.11.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。